Spectral AI, Inc. (MDAI)
| Market Cap | 50.21M -15.8% |
| Revenue (ttm) | 15.39M -44.1% |
| Net Income | -10.09M |
| EPS | -0.33 |
| Shares Out | 32.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,783 |
| Open | 1.610 |
| Previous Close | 1.600 |
| Day's Range | 1.540 - 1.620 |
| 52-Week Range | 1.180 - 2.970 |
| Beta | 1.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 10, 2026 |
About MDAI
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed deci... [Read more]
Financial Performance
In 2025, Spectral AI's revenue was $19.65 million, a decrease of -33.57% compared to the previous year's $29.58 million. Losses were -$7.57 million, -50.05% less than in 2024.
Financial StatementsNews
Spectral AI's DeepView™ System Showcased at the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI submits NTAP application to CMS for DeepView System
Spectral AI (MDAI) announced the submission of a New Technology Add-On Payment, or NTAP, application to the Centers for Medicare & Medicaid Services, or CMS, for its DeepView System utilizing…
Spectral AI Submits New Technology Add-On Payment (NTAP) Application for DeepView™ System
DALLAS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI completes first SIV for DeepView System study
Spectral AI (MDAI) announced the completion of the first Site Initiation Visit, SIV, associated with the commencement of a clinical study designed to support a label expansion of the Company’s…
Spectral AI Announces First Site Initiation Visit for DeepView System™ Clinical Study Supporting Label Expansion Strategy to Burns of the Head, Hands, and Feet
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI Announces Upcoming Presentation at ACS Clinical Congress 2026 Highlighting the Use of Artificial Intelligence and Multi-Spectral Imaging in the Assessment of Burn Wounds
DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Showcases DeepView® System for Burn Indication and KOL Research at Southern Regional Burn Conference
DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
Spectral AI Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A leading convenience store operator is expanding through targeted acquisitions and new builds, focusing on high-margin diesel fuel, value-driven food service, and operational efficiency. Growth is concentrated in the Southwest, with robust financials and mid to high single-digit EBITDA growth expected.
Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference
DALLAS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accu...
Spectral AI Earnings Call Transcript: Q2 2026
FDA De Novo clearance for DeepView System marks a pivotal shift to commercialization, with initial U.S. deployments supported by BARDA and international expansion planned. Q2 2026 saw lower R&D revenue and gross margin due to cost-sharing, but net loss improved year-over-year.
Spectral AI Quarterly report: Q2 2026
Spectral AI has published its Q2 2026 quarterly earnings report on August 11, 2026.
Spectral AI Earnings release: Q2 2026
Spectral AI released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Spectral AI Announces 2026 Second Quarter Financial Results
Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) --...
Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call
DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI transferred with an Outperform at Northland
Northland took over coverage of Spectral AI (MDAI) with an Outperform rating and $4 price target After the “biggest milestone in company history” with FDA De Novo clearance for its…
Spectral AI names Darcy Bajko chief commercial officer
Spectral AI (MDAI) announced the appointment of Darcy Bajko as chief commercial officer, effective July 31. Bajko will lead the commercial functions in support of Spectral AI’s global launch of…
Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education Industry Veteran Brings Two Decades of Experience Driving Growth Through New Produ...
DeepView® System Highlighted at the 2026 British Burn Association Annual Conference
DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI to Participate in 2026 British Burn Association Annual Conference
Company Will Showcase FDA-Cleared DeepView® System for Burn Indication Company Will Showcase FDA-Cleared DeepView® System for Burn Indication
Spectral AI Announces Voting Results of Annual Meeting of Stockholders
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...
Spectral AI price target raised to $4 from $3 at BTIG
BTIG raised the firm’s price target on Spectral AI (MDAI) to $4 from $3 and keeps a Buy rating on the shares after the company announced it received FDA clearance…
Spectral AI receives FDA De Novo clearance for DeepView System
Spectral AI (MDAI) announced that the U.S. Food and Drug Administration, FDA, granted De Novo Classification for its DeepView System. With this classification, Spectral AI is authorized to commence co...
Spectral AI Receives FDA De Novo Clearance for DeepView® System for Burn Indication
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more a...
Spectral AI Earnings Call Transcript: Q1 2026
Q1 2026 saw progress in FDA engagement, BARDA funding, and leadership expansion, with R&D revenue at $4M and a net loss of $3.4M. Commercialization of DeepView is targeted for late 2026, with most BARDA revenue recognized in 2027.